AstraZeneca's VOLGA trial shows 42% lower death risk with IMFINZI and enfortumab vedotin. Can the regimen compete with approved bladder cancer therapy?
AstraZeneca PLC (NASDAQ: AZN) and Amgen Inc. (NASDAQ: AMGN) have reported Phase 3 findings showing that IMFINZI (durvalumab) combined with IMDELLTRA (tarlatamab-dlle) reduced the hazard of death by 58% compared with IMFINZI alone as first-line maintenance treatment for extensive-stage small-cell lung cancer. Presented at the European Society for Medical Oncology Congress 2026 on October 24
Pfizer's 25-valent pediatric vaccine shows strong Phase 2 immune responses, including against serotype 3. Can Phase 3 establish broader protection?
Genmab's Rina-S cut progression risk by 71% and showed an overall survival benefit in Phase 3 ovarian cancer data. What remains before approval?
Palleon's HLX79/E-602 achieved remission in all seven high-dose patients by Week 36. Can the small Phase 2 kidney trial support larger studies?
Tango Therapeutics reports 82% response with vopimetostat and daraxonrasib in pancreatic cancer. Explore the trial results and Phase 3 plans.
Genmab's Rina-S cuts the death hazard by 57% in a Phase 3 ovarian cancer trial. Explore the survival results, treatment potential and FDA outlook.
Roche and Ionis report a 43.1% Phase 3 proteinuria reduction with sefaxersen. Two-year kidney function results remain the next major test.
Vertex's RAINIER trial shows 52% proteinuria reduction with povetacicept ahead of a November 30 FDA decision. Can it stand out in IgA nephropathy?
GondolaBio and Children's Tumor Foundation are partnering on a preclinical NF1 programme, with patient expertise and programme equity at the centre of the deal.